New Medical Advisory Board Appointment

RNS Number : 4411Z

Advanced Oncotherapy PLC

06 February 2014

 

6 February2014                                                                                                                                             

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Medical Physicist Dr Hanne Kooy joins Medical Advisory Board and is appointed Chairman of Product Development Committee

Advanced Oncotherapy (AIM: AVO), the developer of innovative medical technology for cancer treatment, announces the appointment of Dr Hanne M Kooy to its Medical Advisory Board and as Chair the new Product Development Committee to oversee the development of the Company's LIGHT technology. Dr Kooy trained as a physicist, specialising in high energy particle physics, and since 1995 has been Associate Professor in Radiation Therapy at the Department of Radiation Oncology of Harvard Medical School.

After his doctoral studies, an opportunity in medical physics at the University of Rochester arose and he started his career in radiation therapy. Radiation therapy, unlike other medical disciplines, requires active participation of physicists in the direct clinical care of patients. As such, it has been an effective route for introducing engineering technologies. One such technology is proton beam radiation which has become an almost singular focus of Dr Kooy's career. Radiation therapy, like all medical disciplines, has also become fully reliant on information technology. Dr Kooy's interests lie in the effective deployment of these advanced and integrated technologies to support proton radiation therapy.

In addition to his membership of the Medical Advisory Board, Dr Kooy will chair a new committee, the Project Development Committee ("PDC"). The PDC will be tasked with monitoring, evaluating and advising upon completion of the development of Advanced Oncotherapy's LIGHT technology by the Company's wholly owned subsidiary ADAM based at CERN near Geneva. Monitoring the incorporation of this technology into commercial products for end users will also form part of the PDC's remit.

Dr Kooy will join Chairman Dr Nick Plowman, Senior Clinical Oncologist to St Bartholomew's Hospital and The Hospital for Sick Children Great Ormond Street, London;  Dr Jay S Loeffler, Professor of Radiation Oncology at Harvard Medical School and Chair of the Department of Radiation Oncology at the Massachusetts General Hospital; Dr Margaret F Spittle OBE, Department of Oncology, University College London Hospital, and Professor Chris Nutting, Consultant Clinical Oncologist and Chair in Radiation Oncology at the Royal Marsden Hospital and The Institute of Cancer Research in London on the Board.

Advanced Oncotherapy's CEO, Dr Mike Sinclair, said,"The appointment of Hanne provides us with yet another area of key expertise.  Hanne's input and advice, as well as his oversight as chair of the Product Development Committee, should ensure we deliver the robust products at the price points we have intimated to world markets."

Dr Kooy added, "The benefits of proton radiotherapy can only be realized through accessible and affordable proton equipment and we will push our team to deliver on this promise."

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Michael Sinclair (CEO)	Tel: [phone]
Westhouse Securities	Tel: [phone]
Antonio Bossi (Nomad & Joint Broker)
David Coaten
Peterhouse Corporate Finance	Tel: [phone]
Jon Levinson (Joint Broker)
Lucy Williams
Walbrook PR
Anna Dunphy/Mike Wort (Financial PR & IR)	Tel: [phone] or [e-mail]

About Advanced Oncotherapy Plc 

1.   AVO is a provider of radiotherapy services that harnesses the best in modern technology.  As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2.   AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT.  This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3.   AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK through Spire and other hospitals.

 

END

 

 

MSCUGUBAPUPCUQQ